VIENNA—For women with premenopausal breast cancer the benefits of using the most adjuvant endocrine treatment needs to be weighed against additional side effects—according to Marco Colleoni MD from the European Institute of Oncology in Milan. After his talk at the St Gallen breast cancer conference he discussed criteria for individualizing optimal endocrine adjuvant treatments with Oncology Times reporter Sarah Maxwell.
You may also like...
Adjuvant Chemoradiotherapy: Big Gains In Pancreas Cancer 27 Jan, 2008 Androgen Blockade: 18 As Good As 36 Months In Radiotherapy-Treated Prostate Cancer 16 Mar, 2013 Oncology Times Broadcast News with the Audio Journal of Oncology – February 2009 9 Feb, 2009 Multiple Myeloma: Towards A Chronic Disease With Cure On The Horizon 25 Feb, 2008
- Previous story Genetic Tests for Breast Cancer Late Recurrence Risk—Not Yet Ready for Prime Time
- Next story Deep Genomic Profiling in Breast Cancer Promises to Improve Outcomes
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014